Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

#3875

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Aim(s): Aim of this study was to investigate a dose-toxicity relationship, lesion-based and patient-based dose-response relationship in neuroendocrine liver metastases (NELM) treated with holmium-166 radioembolization.

Materials and methods: Single center, retrospective study including all patients with NELM that received holmium-166-radioembolization with available post-treatment SPECT/CT and evaluation imaging. SPECT images were scaled based on the total net administered activity to calculate tumor and whole liver healthy tissue (Dh) absorbed dose. Toxicity was graded by Common Terminology Criteria for Adverse Events (CTCAE), version 5 at baseline and at three months follow-up. Response was determined according to RECIST 1.1 on patient and tumor level.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,